PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. (23rd June 2022) - Lal, A.; Brown, R. C.; Coates, T.; Kalfa, T.; Kwiatkowski, J.; Brevard, J.; Trenor, C.; Wood, K.; Sheth, S.